Proglumetacin (usually as the maleate salt, trade names Afloxan, Protaxon and Proxil) is a non-steroidal anti-inflammatory drug. Proglumetacin is indicated for the pain and inflammation associated with musculoskeletal and joint disorders. The action of proglumetacin maleate is qualitatively the same as that of indomethacin in vivo; that is, it inhibits cyclo-oxygenase in inflammatory sites.

Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the second line treatment of acute pain and primary dysmenorrhoea. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.

Pirprofen is a non-steroidal anti-inflammatory drug, related structurally to drugs such as ibuprofen, ketoprofen and naproxen. Pirprofen was introduced by Ciba-Geigy in 1982 as a treatment for rheumatic diseases. In 1990 due to adverse effects, including some cases of fatal liver toxicity the manufacturers decided to discontinue marketing it worldwide. Pirprofen proved to be useful in the management of both rheumatoid arthritis and osteoarthritis and as an analgesic. In doses of 600-800 mg/d, pirprofen has been found to be as effective as, but not superior to, aspirin 3.6 g/d in relieving the more common symptoms of rheumatoid arthritis. Pirprofen is as effective as, but not superior to, other available NSAIDs in terms of efficacy, tolerability, and incidence of adverse effects. The recommended dosage in osteoarthritis is 450-600 mg/d.

Flufenamic acid is a member of the anthranilic acid derivatives class of NSAID drugs. Like other members of the class, it is a COX inhibitor and prevents the formation of prostaglandins. Flufenamic acid is known to bind to and reduce the activity of prostaglandin F synthase and activate TRPC6.

Proquazon, a non-steroidal anti-inflammatory agent that was studied to use in the management of rheumatoid arthritis and osteoarthritis. The biochemical mechanism of action of proquazon via the inhibition of the core protein synthesis of proteoglycans and the secondary biosynthesis of the glucosamine.

Kebuzone is a cyclooxygenase inhibitor that was used for the treatment of different inflammatory conditions such as thrombophlebitis and rheumatoid arthritis. The current marketing status of the drug is unknown and supposed to be discontinued.

Feprazone is an anti-inflammatory compound developed for the treatment of such conditions as osteoarthritis, rheumatoid arthritis, rheumatic fever and gouty arthritis. The drug was tested in phase III of clinical trials, however its further faith is unknown.

Ibuproxam is a prodrug which metabolizes into ibuprofen and is therefore indicated for the treatment of pain and inflammation. Administration of oral ibuproxam resulted in a significantly higher plasma concentration than administration of an equal dose of ibuprofen after 45 minutes. Despite showing some promise as a NSAID ibuproxam does not appear to have been approved or marketed.

Niflumic acid belongs to the group of nonsteroidal anti-inflammatory drugs (NSAIDs) and used in the treatment of rheumatoid arthritis, and joint and muscular pain. Its mechanism of action is believed to be based on selective inhibition of cycloxygenases-2 that results in antipyretic, analgesic, and anti-inflammatory effects. In addition to these effects on prostaglandin synthesis, it has been shown to act as a positive allosteric modulator on α1β2γ2 and as a negative modulator on α6β2 and α6β2γ2 (and α1β2) GABAA receptors. In addition, was reported, that niflumic acid blocked T-type calcium channels. It is available for clinical use in several European countries.

Oxametacin (1-p-chlorobenzoyl-2-methyl-5-methoxy-3-indolylacethydroxamic acid) is a non-steroidal anti-inflammatory compound that exerts analgesic, antipyretic and anti-inflammatory properties. This drug has been claimed to be effective in the treatment of acute attacks of gout. In the antiproliferative test, oxametacin exhibited leukemic cell lines selectivity against the solid tumor cell lines. Oxametacin also exhibited inhibitory activity toward histone deacetylases and thus could be used as a lead compound in the further development of histone deacetylase inhibitors for anticancer therapy.